MLICM
CLDX icon

Metropolitan Life Insurance Company (MetLife)’s Celldex Therapeutics CLDX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,269
Closed -$137K – 436
2024
Q1 		$137K Buy
3,269
+538
+20% +$22.1K 0.01% 886
2023
Q4 		$108K Hold
2,731
– – 0.01% 1034
2023
Q3 		$75.2K Buy
2,731
+188
+7% +$5.89K ﹤0.01% 1171
2023
Q2 		$86.3K Hold
2,543
– – ﹤0.01% 1097
2023
Q1 		$91.5K Sell
2,543
-290
-10% -$12.5K ﹤0.01% 1031
2022
Q4 		$126K Sell
2,833
-163
-5% -$5.82K 0.01% 931
2022
Q3 		$84.2K Hold
2,996
– – ﹤0.01% 1119
2022
Q2 		$80.8K Hold
2,996
– – ﹤0.01% 1193
2022
Q1 		$102K Sell
2,996
-9,152
-75% -$293K ﹤0.01% 1176
2021
Q4 		$469K Hold
12,148
– – 0.01% 1480
2021
Q3 		$656K Buy
12,148
+1,041
+9% +$48.8K 0.01% 1270
2021
Q2 		$371K Buy
+11,107
New +$305K 0.01% 1712
2018
Q2 		– Sell
-2,348
Closed -$82K – 2458
2018
Q1 		$82K Sell
2,348
-426
-15% -$16.5K ﹤0.01% 2376
2017
Q4 		$118K Sell
2,774
-1,548
-36% -$66.3K ﹤0.01% 2215
2017
Q3 		$185K Sell
4,322
-388
-8% -$14.5K ﹤0.01% 2314
2017
Q2 		$175K Hold
4,710
– – ﹤0.01% 2415
2017
Q1 		$255K Buy
4,710
+446
+10% +$23.2K ﹤0.01% 2110
2016
Q4 		$226K Sell
4,264
-492
-10% -$28K ﹤0.01% 2277
2016
Q3 		$288K Buy
4,756
+29
+0.6% +$1.81K ﹤0.01% 2093
2016
Q2 		$311K Hold
4,727
– – ﹤0.01% 2013
2016
Q1 		$268K Buy
4,727
+94
+2% +$10.6K ﹤0.01% 1980
2015
Q4 		$1.09M Sell
4,633
-126
-3% -$27.5K 0.01% 1142
2015
Q3 		$752K Hold
4,759
– – 0.01% 1351
2015
Q2 		$1.8M Sell
4,759
-247
-5% -$98.1K 0.01% 1007
2015
Q1 		$2.09M Buy
5,006
+221
+5% +$79.1K 0.02% 885
2014
Q4 		$1.31M Hold
4,785
– – 0.01% 1167
2014
Q3 		$930K Hold
4,785
– – 0.01% 1323
2014
Q2 		$1.17M Hold
4,785
– – 0.01% 1255
2014
Q1 		$1.27M Hold
4,785
– – 0.01% 1188
2013
Q4 		$1.74M Buy
4,785
+539
+13% +$208K 0.01% 1041
2013
Q3 		$2.26M Sell
4,246
-269
-6% -$92.2K 0.02% 865
2013
Q2 		$1.06M Buy
+4,515
New +$889K 0.01% 1197

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CLDX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Celldex Therapeutics (CLDX) in Q2 2024, closing a stake of 3,269 shares — an estimated $137K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CLDX in Q2 2013 and held it in 32 quarters. The position peaked at $2.26M in Q3 2013. 182 funds tracked by Wall St. Rank hold CLDX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Celldex Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,269 Celldex Therapeutics shares in Q2 2024, an estimated $137K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Celldex Therapeutics in Q2 2013 and held it in 32 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Celldex Therapeutics position peaked at $2.26M in Q3 2013.
  • 182 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.